^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Biliary Tract Cancer

    Related cancers:
    1d
    Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer. (PubMed, Cancer Sci)
    In conclusion, bile-derived exosomal miR-196a and miR-196b are novel BTC-specific biomarkers. MiR-196a may contribute to early BTC detection, enhance diagnostic accuracy in combination with serum markers, and assist in detecting metastasis.
    Journal
    |
    MIR424 (MicroRNA 424) • CA 19-9 (Cancer antigen 19-9) • MIR196B (MicroRNA 196b)
    1d
    Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, West China Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    1d
    Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, West China Hospital
    New P1/2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    2d
    Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer. (PubMed, Sci Rep)
    In the MSKCC cohort, high tumor mutational burden (TMB-Hmed) correlated with poorer OS (HR = 1.43, P = 0.01), while PBRM1 mutations were associated with improved survival (HR = 0.50, P = 0.02). This study underscores the distinct genomic profiles of GBC and CCA, offering valuable insights into the molecular underpinnings of these aggressive cancers and supporting the development of precision medicine strategies.
    Clinical data • Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • MCL1 (Myeloid cell leukemia 1) • PBRM1 (Polybromo 1) • ARID2 (AT-Rich Interaction Domain 2) • SOX2
    |
    TMB-H • ARID1A mutation
    2d
    An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Haihua Yuan
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • MSI-H/dMMR • BRAF mutation • BRAF wild-type
    |
    Ziihera (zanidatamab-hrii)
    5d
    Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=12, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    6d
    BRAF-Mutant Solid Tumor (PubMed, Gan To Kagaku Ryoho)
    Current BRAF inhibitors mainly target the active BRAF monomer; however, resistance mediated by RAF dimerization frequently occurs. Novel therapeutic approaches including pan-RAF inhibitors and ERK inhibitors are under development to overcome these resistance mechanisms.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    7d
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. (clinicaltrials.gov)
    P2, N=227, Not yet recruiting, GV20 Therapeutics
    New P2 trial
    7d
    ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response. (PubMed, JCO Precis Oncol)
    ERRFI1 mutations represent actionable biomarkers in BTC, with EGFR-targeted therapy demonstrating meaningful clinical benefit in this heavily pretreated population. These findings support integration of ERRFI1 testing into routine molecular profiling of BTC and other EGFR-driven malignancies.
    Clinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ARID1A (AT-rich interaction domain 1A) • ERRFI1 (ERBB Receptor Feedback Inhibitor 1)
    |
    EGFR mutation
    |
    cisplatin • gemcitabine
    7d
    Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer. (PubMed, Expert Opin Emerg Drugs)
    To confirm encouraging first clinical data, larger studies specific for BTC are needed to address tumor heterogeneity and to determine cutoff levels of CLDN-18.2 expression. Such studies are also needed to understand combination options and sequencing of therapies and to further validate novel approaches to fully exploit the potential of targeting CLDN-18.2 in BTC.
    Review • Journal
    |
    CLDN18 (Claudin 18)
    7d
    Review Article: Systemic Treatments for Advanced Cholangiocarcinoma-State of the Art and Future Directions. (PubMed, Aliment Pharmacol Ther)
    Systemic treatment for advanced CCA is rapidly evolving toward biomarker-driven and immunotherapy-based strategies. Integration of molecular profiling and precision oncology may further improve individualised treatment and clinical outcomes.
    Review • Journal • IO biomarker
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR fusion
    |
    cisplatin • gemcitabine
    7d
    CR-001-101: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors (2025-523590-42-00)
    P1/2, N=44, Not yet recruiting, Crescent Biopharma Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation